PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known m 1449A-B/PTO 10/622,010 **Application Number** INFORMATION DISCLOSURE Filing Date July 16, 2003 STATEMENT BY APPLICANT First Named Inventor Joseph Monforte 1631 **Group Art Unit** Michael L. Borin **Examiner Name** 

Attorney Docket Number

**Date Submitted** 

47-030010US

October 29, 2004

		U.S. Patent Do	cument	Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,
Examiner Initials	Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal
<b>%</b>	1	6,406,840		Li et al.	06-18-2002	
	2	6,458,566		Alland et al.	10-01-2002	
V	3	6,500,938		Au-Young et al.	12-31-2002	
						1

(use as many sheets as necessary)

				FOREIGI	N PATENT DOCUMEN			
			Foreign Patent Document			Date of Publication	Pages, Columns, Lines,	۱.
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	<u>L'</u>
up	4	wo	02/008466	A1	Althea Technologies	01-31-2002		
	5	wo	02/40717	A2	Ramon W. Mohanlal	05-23-2002		L
								L
					,			

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, câtalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7				
			-				
			╁				
			╁╴				
			$\dagger$				
			+				
	-		$\dagger$				

Examiner		Date	1/25
Signature	- June	Considered	2-4-05

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A-B/PTO Application Number 10/622,010 July 16, 2003 **NEORMATION DISCLOSURE** Filing Date STATEMENT BY APPLICANT First Named Inventor Joseph Monforte 1743 **Group Art Unit Examiner Name** Unassigned DEC 0 1 2000 e gs many sheets as necessary) Attorney Docket Number 47-030010US December 1, 2003 **Date Submitted** 

TRADENTO		U.S. Patent Document		S. PATENT DOCUMENTS  Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,
xaminer nitials	Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal
-16	1	5,143,854		Pirrung et al.	09-01-1992	
7	2	5,807,522		Brown et al.	09-15-1998	
	3	5,545,522		Van Gelder et al.	08-13-1996	
	4	5,595,895		Miki et al.	01-21-1997	
	5	5,962,271		Chenchik et al.	10-05-1999	
1.	6	6,087,102		Chenchik et al.	07-11-2000	
	7	6,251,639		Kurn	06-26-2001	
	8	6,287,768		Chenchik et al.	09-11-2001	
V	9	6,489,159		Chenchik et al.	12-03-2002	
-						· .

		······································		FOREIGI	N PATENT DOCUMEN	TS		
			Foreign Patent Docu			Date of Publication	Pages, Columns, Lines,	T
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T
The	10	wo	99/35289		Clontech Laboratories, Inc.	07-15-1999		
	11	wo	01/55454		Genetrace Systems, Inc.	08-02-2001		
					·			

	·	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ_
2/2	12	EBERWINE, Amplifications of mRNA Populations Using aRNA Generated from Immobilized Oligo (dT)-T7 Primed cDNA, Biotechniques 20: 584-591 (1996).	
	13	FODOR et al., Light-Directed Spatially Addressable Parallel Chemical Synthesis, Science 251:767-773 (1991).	
	14	PUSKAS et al., RNA Amplification Results in Reproducible Microarray Data with Slight Ratio Bias, Biotechniques 32:6; 1330-1334 (2002).	

Examiner		Date	1
Signature	m	Considered	2-4-05
Cignature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are	. U.S. Patent and e required to respond to a collection of	PTO/SB/08A (04-03) Approved for use through 04/30/2003. OMB 0851-0031 Trademark Office; U.S. DEPARTMENT OF COMMERCE Information unless it contains a valid OMB control number.
Substitute for form 1449A-B/PTO	C	omplete if Known
	Application Number	10/622,010
INFORMATION DISCLOSURE O I P	Filing Date	July 16, 2003
STATEMENT BY APPLICANT	First Named Inventor	Joseph Monforte
	Group Art Unit	1743
E 2013	Examiner Name	Unassigned
(use as many sheets as neosssary)	Attorney Docket Number	47-030010US
470	Date Submitted	December 1, 2003

-3		15	SCHENA et al., Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray, Science 270:467-470 (1995).
	T	16	THOMAS et al., Identification of Toxicologically Predictive Gene Sets Using cDNA Microarrays, Molecular Pharmacology 60: 1189-1194 (2001).
		17	VAN'T VEER et.al., Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer, Nature 415: 530-536 (2002).
	V	18	VAN GELDER et al., Amplified RNA Synthesized from Limited Quantities of Heterogeneous cDNA, Proc. Natl. Acad. Sci. USA 87:5; 1663-1667 (1990).

	•		
Examiner		Date	21/25
Signature	m	Considered	2-5-05

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.